VVOS · Vivos Therapeutics, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Without additional financing, these factors raise substantial doubt regarding the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Oct 27, 2023; bars on opposite sides are not compared.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VVOS
this stock
Vivos Therapeutics, Inc.
|
$6.91M | -85.2% | +16.0% | — | 6.0% |
|
ABT
Abbott Laboratories
|
$193.78B | -11.9% | +5.7% | 31.2 | 1.3% |
|
SYK
Stryker Corp
|
$130.11B | -5.6% | +11.2% | 35.2 | 2.2% |
|
MDT
Medtronic plc
|
$116.83B | -5.7% | +8.4% | 24.5 | 1.4% |
|
BSX
Boston Scientific Corp
|
$74.64B | -46.1% | +12.5% | 20.9 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Oct 27, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VVOS | -5.2% | -26.7% | -80.5% | -26.5% | -85.2% |
| SPY | -0.1% | +4.1% | +12.4% | +3.4% | +13.3% |
| vs SPY | -5.1% | -30.8% | -92.9% | -30.0% | -98.5% |